FOCL
Price
$2.82Alerts
Change
-$0.28 (-9.03%)
Updated
Nov 19 closing price
Capitalization
156.76M
Intraday BUY SELL Signals
STXS
Price
$1.04Alerts
Change
+$0.09 (+9.47%)
Updated
Nov 19, 04:59 PM (EDT)
Capitalization
109.22M
99 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

FOCL vs STXS

FOCL vs STXS Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
FOCL vs. STXS commentary
Nov 20, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is FOCL is a Hold and STXS is a StrongBuy.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for FOCL with price predictions
Nov 18, 2026

FOCL sees its 50-day moving average cross bearishly below its 200-day moving average

The 50-day moving average for FOCL moved below the 200-day moving average on October 19, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 06, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on FOCL as a result. In 70 of 91 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 77%.

The Moving Average Convergence Divergence Histogram (MACD) for FOCL turned negative on November 06, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 40 similar instances when the indicator turned negative. In 34 of the 40 cases the stock turned lower in the days that followed. This puts the odds of success at 85%.

FOCL moved below its 50-day moving average on November 05, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where FOCL declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.

The Aroon Indicator for FOCL entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where FOCL's RSI Indicator exited the oversold zone, 28 of 39 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 72%.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 7 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +4.08% 3-day Advance, the price is estimated to grow further. Considering data from situations where FOCL advanced for three days, in 185 of 242 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.

FOCL may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 13 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of 61 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-48.608) is normal, around the industry mean (14.423). P/E Ratio (-3.192) is within average values for comparable stocks, (11.188). FOCL's Projected Growth (PEG Ratio) (8.100) is very high in comparison to the industry average of (2.016). Dividend Yield (0.000) settles around the average of (0.134) among similar stocks. P/S Ratio (1.919) is also within normal values, averaging (4.260).

The Tickeron Price Growth Rating for this company is 65 (best 1 - 100 worst), indicating fairly steady price growth. FOCL’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. FOCL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 74, placing this stock worse than average.

A.I.Advisor
a Summary for STXS with price predictions
Nov 19, 2026

STXS in upward trend: price may jump up because it broke its lower Bollinger Band on October 29, 2026

STXS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 25 of 29 cases where STXS's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 86%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where STXS's RSI Indicator exited the oversold zone, 25 of 30 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 83%.

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 50 of 66 cases where STXS's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 76%.

The Moving Average Convergence Divergence (MACD) for STXS just turned positive on November 18, 2026. Looking at past instances where STXS's MACD turned positive, the stock continued to rise in 41 of 51 cases over the following month. The odds of a continued upward trend are 80%.

Following a +14.50% 3-day Advance, the price is estimated to grow further. Considering data from situations where STXS advanced for three days, in 152 of 204 cases, the price rose further within the following month. The odds of a continued upward trend are 75%.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 18, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on STXS as a result. In 78 of 104 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 75%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where STXS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.

The Aroon Indicator for STXS entered a downward trend on November 06, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 18 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 80 (best 1 - 100 worst), indicating slightly worse than average price growth. STXS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of 94 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (8.921) is normal, around the industry mean (4.964). P/E Ratio (-4.542) is within average values for comparable stocks, (40.591). Projected Growth (PEG Ratio) (12.600) is also within normal values, averaging (4.143). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (4.248) is also within normal values, averaging (56.876).

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. STXS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

FUNDAMENTALS RATINGS
FOCL vs STXS: Fundamental Ratings
FOCL
STXS
OUTLOOK RATING
1..100
5715
VALUATION
overvalued / fair valued / undervalued
1..100
61
Fair valued
94
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
6580
P/E GROWTH RATING
1..100
1318
SEASONALITY SCORE
1..100
5085

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

FOCL's Valuation (61) in the Biotechnology industry is somewhat better than the same rating for STXS (94) in the Medical Specialties industry. This means that FOCL’s stock grew somewhat faster than STXS’s over the last 12 months.

FOCL's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as STXS (100) in the Medical Specialties industry. This means that FOCL’s stock grew similarly to STXS’s over the last 12 months.

FOCL's SMR Rating (100) in the Biotechnology industry is in the same range as STXS (100) in the Medical Specialties industry. This means that FOCL’s stock grew similarly to STXS’s over the last 12 months.

FOCL's Price Growth Rating (65) in the Biotechnology industry is in the same range as STXS (80) in the Medical Specialties industry. This means that FOCL’s stock grew similarly to STXS’s over the last 12 months.

FOCL's P/E Growth Rating (13) in the Biotechnology industry is in the same range as STXS (18) in the Medical Specialties industry. This means that FOCL’s stock grew similarly to STXS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
FOCLSTXS
RSI
ODDS (%)
Bullish Trend 2 days ago
72%
Bullish Trend 1 day ago
83%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
77%
Bullish Trend 1 day ago
76%
Momentum
ODDS (%)
Bearish Trend 2 days ago
77%
Bearish Trend 1 day ago
75%
MACD
ODDS (%)
Bearish Trend 2 days ago
85%
Bullish Trend 1 day ago
80%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
84%
Bullish Trend 1 day ago
82%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
85%
Bullish Trend 1 day ago
79%
Advances
ODDS (%)
Bullish Trend 18 days ago
76%
Bullish Trend 1 day ago
75%
Declines
ODDS (%)
Bearish Trend 3 days ago
84%
Bearish Trend 4 days ago
82%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
75%
Bullish Trend 1 day ago
86%
Aroon
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 1 day ago
88%
COMPARISON
Comparison
Nov 20, 2026
Stock price -- (FOCL: $3.10 vs. STXS: $0.95)
Brand notoriety: FOCL and STXS are both not notable
FOCL represents the Medical Distributors, while STXS is part of the Pharmaceuticals: Other industry
Current volume relative to the 65-day Moving Average: FOCL: 179% vs. STXS: 119%
Market capitalization -- FOCL: $156.76M vs. STXS: $109.22M
FOCL [@Medical Distributors] is valued at $156.76M. STXS’s [@Pharmaceuticals: Other] market capitalization is $109.22M. The market cap for tickers in the [@Medical Distributors] industry ranges from $44.8K to $123.68B. The market cap for tickers in the [@Pharmaceuticals: Other] industry ranges from $126 to $159.96B. The average market capitalization across the [@Medical Distributors] industry is $23.75B. The average market capitalization across the [@Pharmaceuticals: Other] industry is $9.78B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

FOCL’s FA Score shows that 1 FA rating(s) are green while STXS’s FA Score has 1 green FA rating(s).

  • FOCL’s FA Score: 1 green, 4 red.
  • STXS’s FA Score: 1 green, 4 red.
According to our system of comparison, FOCL is a better buy in the long-term than STXS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

FOCL’s TA Score shows that 4 TA indicator(s) are bullish while STXS’s TA Score has 5 bullish TA indicator(s).

  • FOCL’s TA Score: 4 bullish, 6 bearish.
  • STXS’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, STXS is a better buy in the short-term than FOCL.

Price Growth

FOCL (@Medical Distributors) experienced а -12.18% price change this week, while STXS (@Pharmaceuticals: Other) price change was +5.12% for the same time period.

The average weekly price growth across all stocks in the @Medical Distributors industry was -12.67%. For the same industry, the average monthly price growth was -25.45%, and the average quarterly price growth was -27.62%.

The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was -4.88%. For the same industry, the average monthly price growth was -2.33%, and the average quarterly price growth was +6.73%.

Reported Earning Dates

STXS is expected to report earnings on Feb 26, 2027.

Industries' Descriptions

@Medical Distributors (-12.67% weekly)

Healthcare distribution market can be segmented into pharmaceutical product distribution services, medical device distribution services, and biopharmaceutical product distribution services. In addition to serving as intermediaries, many medical distributors also purchase and take legal ownership of pharmaceuticals and manage inventory and credit risk. According to a Deloitte report, pharmaceutical distributors’ core services of efficient product distribution, inventory management, financial risk management, and information-sharing generate $33 billion-$53 billion in value annually to the U.S. health care ecosystem. Some prominent players in the overall medical distribution industry include McKesson Corporation, AmerisourceBergen Corporation, Cardinal Health, Inc. and Patterson Companies, Inc.

@Pharmaceuticals: Other (-4.88% weekly)

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

View a ticker or compare two or three
Interact to see
Advertisement

FOCL and

Correlation & Price change

A.I.dvisor tells us that FOCL and AORT have been poorly correlated (+29% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that FOCL and AORT's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To FOCL
1D Price
Change %
FOCL100%
-9.03%
AORT - FOCL
29%
Poorly correlated
-0.05%
UFPT - FOCL
20%
Poorly correlated
-2.20%
SENS - FOCL
20%
Poorly correlated
-8.57%
STXS - FOCL
16%
Poorly correlated
+6.75%
ACH - FOCL
16%
Poorly correlated
N/A
More

STXS and

Correlation & Price change

A.I.dvisor indicates that over the last year, STXS has been loosely correlated with SMTI. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if STXS jumps, then SMTI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To STXS
1D Price
Change %
STXS100%
+6.75%
SMTI - STXS
38%
Loosely correlated
-0.18%
TWST - STXS
36%
Loosely correlated
-4.07%
CERS - STXS
35%
Loosely correlated
-2.06%
VCYT - STXS
33%
Poorly correlated
-2.07%
SHC - STXS
32%
Poorly correlated
-0.43%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
AELV26.22N/A
N/A
Harbor AlphaEdge Large Cap Value ETF (AELV)
FMB49.24-0.08
-0.16%
First Trust Managed Municipal ETF (FMB)
MARM34.50-0.09
-0.26%
FT Vest U.S. Equity Max Buffer ETF - March (MARM)
EMF18.62-0.32
-1.69%
Templeton Emerging Markets Fund
FDNI23.41-0.54
-2.27%
First Trust Dow Jones International Internet ETF (FDNI)